Search
for
Sort by
Research 61–90 of 1000+
- Invasion and increased expression of S100A4 and CYR61 in mesenchymal transformed breast cancer cells is downregulated by GnRH
- Amphiregulin in Fibrotic Diseases and Cancer
- Hub biomarkers in ultrasound-guided bladder cancer and osteosarcoma: Myosin light chain kinase and caldesmon
- Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells
- Effectiveness and safety of standard chemotherapy in older patients with ovarian cancer: a retrospective analysis by age group and treatment regimen
- Predisposing and Overall Effects of Reproductive Hormones on Breast Cancer: A Review
- Androgen Receptor Mutations and Polymorphisms in African American Prostate Cancer
- Matrix-Degrading Type II Transmembrane Serine Protease Matriptase: Its Role in Cancer Development and Malignancy
- Molecular Mechanisms of Vitexin: An Update on Its Anti-Cancer Functions
- Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer
- BRAF Inhibitor Dabrafenib in Patients with Metastatic <i>BRAF</i>-Mutant Thyroid Cancer
- LGR5 is a Marker of Poor Prognosis in Glioblastoma and is Required for Survival of Brain Cancer Stem‐Like Cells
- Indian Hedgehog Controls Proliferation and Differentiation in Skin Tumorigenesis and Protects against Malignant Progression
- Anlotinib or Bevacizumab Combined with Taxane/Capecitabine for the Second-Line or Subsequent Treatment of HER-2 Negative Metastatic Breast Cancer: A Retrospective Cohort Study
- Supplementary Material for: Patient Preferences: Results of a German Adaptive Choice-Based Conjoint Analysis (Market Research Study Sponsored by Eli Lilly and Company) in Patients on Palliative Treatment for Advanced Breast Cancer
- Supplementary Material for: Patient Preferences: Results of a German Adaptive Choice-Based Conjoint Analysis (Market Research Study Sponsored by Eli Lilly and Company) in Patients on Palliative Treatment for Advanced Breast Cancer
- The role of Pygo2 during intestinal tumor initiation and progression in vivo
- Levels of sex steroids in lung tissues of patients with non‑small cell lung cancer after COVID‑19 of different severity
- Sacituzumab tirumotecan (sac-TMT/MK-2870/SKB264): a novel antibody–drug conjugate in breast cancer
- Genotypic and Phenotypic Study of PDCD4 gene Concerning micro RNA-21 and micro RNA-449b Polymorphism in Breast Cancer
- Patched1 Functions as a Gatekeeper by Promoting Cell Cycle Progression
- The natural history of androgenetic alopecia
- The Double Edge Sword of Testosterone’s Role in the COVID-19 Pandemic
- The Important Role of Leptin in Modulating the Risk of Dermatological Diseases
- Evaluation of ChatGPT Dermatology Responses to Common Patient Queries
- Age-associated inflammation connects RAS-induced senescence to stem cell dysfunction and epidermal malignancy
- Activated Polyamine Catabolism Depletes Acetyl-CoA Pools and Suppresses Prostate Tumor Growth in TRAMP Mice
- Actinic keratosis: a clinical and epidemiological revision
- Role of sgk1 in cancer: a bibliometric analysis from 2013 to 2023—review article
- Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study